SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 21, 2025

Regenerative Medical Technology Group Inc.
(Exact name of registrant as specified in its charter)

Nevada	000-56010	88-0492191
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

433 Plaza Real Suite 275 Boca Raton, Florida	33432
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (800) 956-3935

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act: None.

SECTION 2 – FINANCIAL INFORMATION

Item 2.02 Results of Operations and Financial Condition.

On May 21, 2025, we issued a press release concerning our revenue results, positive operating cash flow for the quarter ended March 31, 2025, our new membership plan, and other matters.

The press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. The information furnished under this Item 2.02 and Item 9.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any registration statement or other filing under the Securities Act of 1933, as amended, regardless of any general incorporation by reference language in such filing, except as shall be expressly set forth by specific reference in any such filing.

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Press Release, dated May 21, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Regenerative Medical Technology Group Inc.

/s/ David Christensen

David Christensen
Chief Executive Officer

Date: May 21, 2025

EX-99.1 2 ea024297301ex99-1_regenerat.htm PRESS RELEASE, DATED MAY 21, 2025

Exhibit 99.1

Regenerative Medical Technologies Group Increases Q1 2025 Sales By 67% Over Q1 2024. Achieves Operating Profit for the Quarter of $134,000

LAS VEGAS, NV, May 21, 2025 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Regenerative Medical Technologies Group, Inc. (the "Company" or "RMTG"), a regenerative medicine company is pleased to announce that sales for its first quarter of 2025 surpassed $1.35M, a 67% increase over sales for the same quarter in 2024. The Company also achieved operational profits of $134,000 for the quarter.

As sales continue to increase and the overall industry continues to gain momentum, the Company has introduced a new revenue stream. The Company has commenced selling Turnkey exclusive memberships, where new members pay a fee upfront in exchange for turnkey assistance in setting up a regenerative medical clinic in their area along with continuous training and support. The members are bound to purchase all supplies exclusively from RMTG. RMTG expects to onboard one new member per quarter for now and expects to increase this rate of onboarding significantly as of next year.

"We are extremely pleased with this quarter's performance and continuing our significant trend of positive operating income. We expect to see continued revenue growth in our four lines of business and sustained increases in operating income," said David Christensen CEO/President of the Company.

The Company expects to issue official guidance on revenues for the remainder of this year and for the next 2 years in a subsequent press release in the near future.

This press release should be read in conjunction with all of the company's filings on www.sec.gov

About Regenerative Medical Technologies Group, Inc.

Regenerative Medical Technologies Group, Inc. is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in 21 countries that carry its banner and has its own clinic in Cancun. The Company distributes stem cells and other regenerative based cell lines and equipment internationally and also specializes in education and training physicians in the area of regenerative medicine.

For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com

Forward Looking Statements

Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Regenerative Medical Technologies Group, Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Regenerative Medical Technologies Group, Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

For further information, please contact: investor.relations@regenmedtechgroup.com